{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"12.29","upperLimit":"24.38","value":"17.22"},{"groupId":"OG001","lowerLimit":"13.11","upperLimit":"22.31","value":"17.00"},{"groupId":"OG002","lowerLimit":"14.55","upperLimit":"27.24","value":"24.21"},{"groupId":"OG003","lowerLimit":"10.68","upperLimit":"21.72","value":"15.93"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"154"},{"groupId":"OG001","value":"148"},{"groupId":"OG002","value":"65"},{"groupId":"OG003","value":"148"}],"units":"Participants"}],"title":"PD-L1 expression positive (TIP>=1%)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"12.68","upperLimit":"18.53","value":"15.06"},{"groupId":"OG001","lowerLimit":"11.50","upperLimit":"21.29","value":"14.26"},{"groupId":"OG002","lowerLimit":"8.97","upperLimit":"17.51","value":"14.46"},{"groupId":"OG003","lowerLimit":"12.39","upperLimit":"16.69","value":"13.93"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"190"},{"groupId":"OG001","value":"189"},{"groupId":"OG002","value":"79"},{"groupId":"OG003","value":"181"}],"units":"Participants"}],"title":"PD-L1 expression negative (TIP<1%)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"344"},{"groupId":"OG001","value":"337"},{"groupId":"OG002","value":"144"},{"groupId":"OG003","value":"329"}],"units":"Participants"}],"description":"Overall survival by baseline PD-L1 expression levels (positive vs. negative). PD-L1 expression level is based on the Tumor and Immune Cell Positivity (TIP) score method as: PD-L1 Positive (TIP ≥ 1%) or PD-L1 Negative (TIP \\< 1%).","dispersionType":"95% Confidence Interval","groups":[{"description":"Durvalumab 1500 mg every 4 weeks (Q4W)","id":"OG000","title":"Durva 1500 mg"},{"description":"Tremelimumab 300 mg × 1 dose + durvalumab 1500 mg Q4W","id":"OG001","title":"Treme 300 mg x1 Dose + Durva 1500 mg"},{"description":"Tremelimumab 75 mg Q4W × 4 doses + durvalumab 1500 mg Q4W","id":"OG002","title":"Treme 75 mg x4 Doses + Durva 1500 mg"},{"description":"Sorafenib 400 mg twice daily (BID)","id":"OG003","title":"Sora 400 mg"}],"paramType":"MEDIAN","populationDescription":"A subset of FAS who had non-missing baseline PD-L1 status. T75+D arm was closed during study.","reportingStatus":"POSTED","timeFrame":"From the date of randomization until death due to any cause, assessed until the final analysis DCO (27Aug2021, to a maximum of approximately 46 months).","title":"Overall Survival (OS) by PD-L1","type":"SECONDARY","unitOfMeasure":"months"}